论文部分内容阅读
目的 评价泰索帝 (docetaxel)单药治疗晚期非小细胞肺癌的客观有效率及毒性。方法 使用泰索帝单药治疗晚期非小细胞肺癌患者 15例 ,其中男性 10例 ,女性 5例。初治 11例 ,复治 4例。Ⅲ期患者 7例 ,Ⅳ期患者 8例。给予泰索帝 75～ 10 0mg/m2 。在给药前 1天开始口服地塞米松 7.5mg ,每天 2次 ,连续 5天。 结果 15例患者均完成 2个疗程以上的化疗。 3例患者达到部分缓解 ,6例患者病灶稳定 ,6例病情进展。总有效率为 2 0 .0 %。主要不良反应为骨髓抑制。 4例患者因白细胞下降导致感染发热。有 1例患者发生Ⅲ度过敏反应。其他不良作用包括脱发、肌肉酸痛、周围神经麻痹、面部潮红、液体潴留。结论 泰索帝75～ 10 0mg/m2 单药治疗非小细胞肺癌单药的有效率为 2 0 .0 % ,该药主要的不良作用是骨髓抑制。
Objective To evaluate the objective efficacy and toxicity of docetaxel monotherapy for advanced non-small cell lung cancer. Methods There were 15 patients with advanced non-small cell lung cancer treated with Taxotere alone, including 10 males and 5 females. 11 cases were initially treated and 4 cases retreated. There were 7 patients in stage III and 8 in stage IV. Give Taxotere 75 to 100 mg/m2. Oral dexamethasone 7.5 mg was administered orally twice a day for 5 days on the day before dosing. Results 15 patients completed more than two courses of chemotherapy. Three patients achieved partial remission, six patients had stable lesions, and six patients progressed. The total effective rate is 20%. The main adverse reaction was myelosuppression. Four patients developed fever due to a decline in leukocytes. A third degree allergic reaction occurred in one patient. Other adverse effects include hair loss, muscle aches, peripheral nerve palsy, facial flushing, and fluid retention. Conclusions The effective rate of monotherapy for monotherapy of non-small cell lung cancer by Taxotere 75-100 mg/m2 is 20.0 %. The main adverse effect of Taxotere is bone marrow suppression.